This presentation explores the use of bacteriophage (phage) cocktails as a targeted treatment for bacterial sexually transmitted diseases (STDs); including gonorrhea, chlamydia, syphilis, and genital mycoplasmosis. It discusses the growing challenge of antibiotic resistance; the precision targeting capabilities of phages, potential clinical applications, and the future of phage therapy in STD management. Research findings, clinical perspectives, and key references are provided to support the development of alternative therapies to combat drug-resistant pathogens